The Global Lyophilisation for Pharmaceuticals products and services Market will reach $3.09BN in 2014

Wednesday 2 April 2014, Amsterdam

A new report calculates that the global lyophilisation for pharmaceuticals products and services market will reach $3.09bn in 2014 with revenues showing strong growth to 2024. These revenue forecasts and others appear in the latest report Lyophilisation for Pharmaceuticals: Products and Services 2014-2024 & Prospects for Leading Companies.

Lyophilisation or freeze drying is the preferred method of preservation in the biotechnology industry; in general it is used to preserve vaccines, pharmaceuticals, and other proteins in order to improve stability and long term storage stability of pharmaceutical products. This exciting manufacturing process is suitable for a range of therapeutic areas and healthcare applications that include vaccines, biosimilars, monoclonal antibodies, interferons, insulins, plasma and recombinant coagulation factors and other recombinant hormones.  Although the lyophilisation for pharmaceuticals market is reaching maturity, it is still expected to grow strongly throughout 2014-2024, driven by the commercial success of current therapeutic applications, biotech and process innovations, advances in technology, improvements in regulation, and rapid commercialisation of products and services in the emerging markets of the BRIC Nations (Brazil, Russia, India and China) and MKT Nations (Mexico, South Korea and Turkey).

Suzanne Armengol, a pharmaceutical and medical devices analyst explains: “Lyophilisation is a process more commonly known as freeze-drying. It is a dehydration process used to preserve perishable products and materials, making the products more convenient for storage and transport. This process is in growing demand for the biopharmaceutical segment and it is currently identified as the preferred method of preservation in the biotechnology industry. Currently, it is used to preserve vaccines, pharmaceuticals, and other proteins in order to improve the stability and long term storage stability of pharmaceutical products. The pharmaceutical industry and contract manufacturing organisations (CMOs) are focusing on tapping this large demand for such specialised niche technologies. In particular, there will be an accelerated growth in the lyophilisation for pharmaceuticals market in the BRIC Nations (Brazil, Russia, India and China) and MKT Nations (Mexico, South Korea and Turkey) during the period 2014 to 2024.

Advances in the lyophilisation technologies in line with the QbD and cGMP regulations, such as ControLyo, SMART technology, Ice Fog and the innovative Process Analytical Technologies (PAT) will extend the range of equipments for new possible therapeutic applications and may provide solutions to the problem of product degradation when reaction is above glass transition temperature, and concerns related to high costs and extended process timings. Taking advantage of the opportunities in this fast-moving market will require companies to understand the essential unmet needs of the industry and navigate challenges such as the promising substitute technologies for lyophilisation, stringent regulations, high costs and product formulation challenges.”

The US is currently the leading national market; however, in time, supported by rapid translation of research into commercial products, the emerging economies in the Asia Pacific region (composed by its leading countries Japan, China, India and South Korea), are predicted to overcome the European markets in 2024, aiming to become the second-largest regional market.

The 254 page report provides revenue forecasts to 2024 for the world lyophilisation for pharmaceuticals market and leading regional markets. It forecasts sales in the US, Japan, Germany, France, Italy, Spain, UK, China, India, Russia, Brazil, Turkey, Mexico and South Korea; as well as group forecasts for market regions like EU5, BRIC Nations, MKT Nations and Asia-Pacific. The report also forecasts sales for the submarket segments like cGMP lyophilisers, laboratory lyophilisers, lyophilisation services and forecasts for the most lyophilisation applications (monoclonal antibodies, insulin, interferons, other recombinant hormones, plasma and recombinant coagulation factors, other protein therapeutics, biosimilars and vaccines). It also includes three exclusive interviews with industry experts regarding insightful unmet needs and current market trends.

Lyophilisation for Pharmaceuticals: Products and Services 2014-2024 & Future Prospects for Leading Companies adds to the extensive range of analytical reports on industries and markets in healthcare.